Home/Pipeline/BT8009

BT8009

Solid Tumors (targeting Nectin-4)

Phase 1/2Active

Key Facts

Indication
Solid Tumors (targeting Nectin-4)
Phase
Phase 1/2
Status
Active
Company

About Bicycle Therapeutics

Bicycle Therapeutics aims to become a world-leading solid tumor medicines company by leveraging its proprietary Bicycle® platform to create precision-guided therapeutics. Its core technology enables the rapid discovery and development of constrained peptides with high affinity and selectivity for challenging targets. The company is progressing multiple clinical-stage oncology assets and has established creative collaborative relationships to expand its technology into anti-infective, cardiovascular, and CNS diseases.

View full company profile